Loading ...

erlotinib/cyclopamine-encapsulating irinotecan-containing PEG-based polymer nanoparticles colloid

Based on

1 Articles
2016 Most recent source

Composition

Image only illustrates the order and placement of components as described in literature.

1

erlotinib/cyclopamine mixture

ET/CP
Type Complex Compound
Formula
Role core
2

irinotecan-modified polyethyleneglycol-based 4-phenylazobenzoic acid derivative

AZO-C6-PEG-S-Ir polymer
Type Polymer
Formula
Role layer

Properties

General physical and chemical properties

Property Value Nanomaterial Variant Source
colloidal stability

More information/entries available to subscribers only.

Or, view sample content

Characterization

Method Nanomaterial Variant Source
dynamic light scattering

More information available to subscribers only.

Or, view sample content

Biological effects

Biological system Test details Nanomaterial Variant Source
female BALB/c nude mice bearing with MCF-7 xenograft tumor

More information/entries available to subscribers only.

Or, view sample content

Preparation

Method 1

Type: Physical formation
Source:
Starting materials
Product

erlotinib/cyclopamine-encapsulating irinotecan-containing PEG-based polymer nanoparticles colloid

Hydrodynamic diameter: ~ 40 nm

Medium: Dulbecco's modified Eagle medium containing fetal bovine serum

Support: none

Method 2

Type: Physical formation
Source:
Starting materials
  • erlotinib
  • irinotecan-modified polyethyleneglycol-based 4-phenylazobenzoic acid derivative
  • cyclopamine
  1. qQqSFeimud646TVITdwLKRYXm8RhnluMGtb6Wq4wDSZm0Cd9tL4iW0EFp5G9r5vlCV5
Product

erlotinib/cyclopamine-encapsulating irinotecan-containing PEG-based polymer nanoparticles colloid

Size: not specified

Medium/Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial